Overview

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Status:
Not yet recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvant Trial Type: Interventional prospective Type of control: Historical Route of administration: IV Treatment Groups: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Number of trial participants: 27 Estimated enrollment period: 24 months Estimated duration of trial: 3.5 Years Duration of Participation: 9 months Estimated average length of treatment per patient: 9 months

Phase:

Phase 2

Details

Lead Sponsor:

Baylor College of Medicine

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Folfirinox
Pembrolizumab